Investigating the effect of furazolidone drug for the treatment of stomach bacterial infectio

Phase 2

• Conditions: H. pylori infection.; Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere; B96.81

• Registration Number: IRCT20230202057305N1
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 March 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 135

Inclusion Criteria

Confirmation of H. pylori infection in patients by standard diagnostic methods
Over seventeen years of age

Exclusion Criteria

History of known drug sensitivity to the studied drug regimen
pregnancy
Having chronic diseases (pulmonary, kidney, liver)
Unwillingness to participate in the study
Patients treated with other treatment methods such as probiotics, other antibiotics, etc.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Eradication and safety of drug regimens containing furazolidone in patients with H. pylori infection. Timepoint: Investigating the eradication rate of H. pylori two weeks after the end of the treatment regimen. Method of measurement: Standard diagnostic methods include RUT, histology staining, bacterial culture, antigen test.

Secondary Outcome Measures

Name	Time	Method
H. pylori eradication, drug safety. Timepoint: Two weeks after the end of the eradication treatment. Method of measurement: Urea breath test, fecal antigen, bacterial culture, histology.